Merck’s Bavencio hits targets in bladder cancer interim analysis

7th January 2020 Uncategorised 0

Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.

More: Merck’s Bavencio hits targets in bladder cancer interim analysis
Source: News